Natixis Advisors LLC boosted its holdings in Endava plc (NYSE:DAVA – Free Report) by 5.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,317 shares of the company’s stock after buying an additional 1,743 shares during the quarter. Natixis Advisors LLC owned approximately 0.05% of Endava worth $800,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of DAVA. Paradice Investment Management LLC purchased a new position in Endava in the second quarter valued at $18,695,000. Millennium Management LLC increased its holdings in Endava by 64.5% in the second quarter. Millennium Management LLC now owns 571,021 shares of the company’s stock valued at $16,697,000 after buying an additional 223,964 shares during the last quarter. Mawer Investment Management Ltd. purchased a new position in Endava in the second quarter valued at $4,915,000. Acadian Asset Management LLC increased its holdings in Endava by 4,578.4% in the second quarter. Acadian Asset Management LLC now owns 169,500 shares of the company’s stock valued at $4,949,000 after buying an additional 165,877 shares during the last quarter. Finally, Horrell Capital Management Inc. increased its holdings in Endava by 76.5% in the third quarter. Horrell Capital Management Inc. now owns 150,000 shares of the company’s stock valued at $3,831,000 after buying an additional 65,000 shares during the last quarter. Hedge funds and other institutional investors own 62.23% of the company’s stock.
Endava Price Performance
Shares of DAVA opened at $28.48 on Thursday. Endava plc has a fifty-two week low of $23.28 and a fifty-two week high of $81.06. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 204.29, a price-to-earnings-growth ratio of 2.05 and a beta of 1.21. The firm has a 50-day simple moving average of $26.08 and a 200-day simple moving average of $28.29. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 1.90.
Analyst Ratings Changes
Several equities analysts have issued reports on the company. TD Cowen raised their price objective on Endava from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Citigroup dropped their price objective on Endava from $30.00 to $27.00 and set a “neutral” rating on the stock in a report on Monday, October 28th. JPMorgan Chase & Co. raised their price objective on Endava from $41.00 to $47.00 and gave the stock an “overweight” rating in a report on Friday, September 6th. Bank of America assumed coverage on Endava in a report on Friday, November 22nd. They set a “neutral” rating and a $29.00 price objective on the stock. Finally, Guggenheim dropped their price objective on Endava from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.83.
View Our Latest Stock Analysis on DAVA
Endava Company Profile
Endava plc provides technology services for clients in the consumer products, healthcare, mobility, and retail verticals in North America, Europe, the United Kingdom, and internationally. It offers ideation and production services in the payments and financial services, telecommunications, media, and technology verticals; and business analysis, data analytics, program management, digital product strategy, private equity value enhancement, IT strategy, architecture, extended reality, machine learning and artificial intelligence, product design, and user experience and visual design services.
Further Reading
- Five stocks we like better than Endava
- Insider Buying Explained: What Investors Need to Know
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Invest in Small Cap StocksĀ
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- With Risk Tolerance, One Size Does Not Fit All
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Endava Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endava and related companies with MarketBeat.com's FREE daily email newsletter.